Objective: Melasma has been shown to have a significant emotional and psychologic impact on affected patients. We aimed to investigate the demographic features and clinical characteristics of melasma patients and the effect of the disease on the quality of life. Material and Methods: Medical records of 80 melasma patients who presented to outpatient clinic and 80 adult patients without facial dermatosis but had skin disease as control group were reviewed. Dermatological Quality of Life Index (DLQI) was filled out in the form of a questionnaire and the quality of life of both groups was measured. Results: A significant difference was found between the patient and control groups in marital status, income level and drug use due to additional systemic disease. Median DLQI score was 4.00 in the patient group; while median DLQI score was 5.50 in the control group. Patients who received previous treatment for melasma or other dermatological diagnoses had higher DLQI scores than patients who did not receive such treatment. Conclusion: The lower the education level, the higher the rate of melasma may be due to the lack of knowledge about sun protection. The epidermal type melasma was detected the most. In the present study, it was found that the negative effects of melasma on the quality of life of the patients were less than control group. In the control group, the negative effects of other skin diseases on the dermatological quality of life were much stronger than the effects on patient group.
Keywords: Melasma; life quality; epidemiologic factors
Amaç: Melazmanın etkilenen hastalar üzerinde önemli bir duygusal ve psikolojik etkisi olduğu gösterilmiştir. Melazma hastalarının demografik yapısını, klinik özelliklerini ve hastalığın yaşam kalitesine olan etkisini araştırmayı amaçladık. Gereç ve Yöntemler: Dermatoloji polikliniğine başvuran melazma tanısı olan 80 ve kontrol grubu olarak fasiyal dermatozu olmayan fakat deri hastalığı olan 80 erişkin hastaların tibbi kayıtları incelenmiştir. Hastalara Dermatolojik Yaşam Kalite İndeksi (DYKİ) anket şeklinde doldurtularak her iki grubun yaşam kalitesi ölçülmüştür. Bulgular: Hasta ve kontrol grupları arasında medeni durum, gelir düzeyi ve ek sistemik hastalığa bağlı ilaç kullanımında anlamlı farklılık bulundu. Hasta grubunda DYKİ skoru ortanca değeri 4.00 iken kontrol grubunda DYKİ skoru ortanca değeri 5.50 idi. Melazma veya diğer dermatolojik tanılar için öncesinde tedavi alan hastalarda ise DYKİ skoru almayanlara göre daha yüksekti. Sonuç: Eğitim düzeyi düşükçe melazma oranının artması, güneşten korunma konusundaki bilgi eksikliği kaynaklı olabilir. En sık epidermal tip melazma tespit edilmiştir. Bu çalışmada, melazmanın hastaların yaşam kalitesine olumsuz etkilerinin seçilen kontrol grubuna göre daha az olduğu görüldü. Kontrol grubunda, diğer cilt hastalıklarının dermatolojik yaşam kalitesi üzerindeki olumsuz etkileri hasta grubuna göre çok daha güçlüdür.
Anahtar Kelimeler: Melazma; yaşam kalitesi; epidemiyolojik etkenler
- Victor FC, Gelber J, Rao B. Melasma: a review. J Cutan Med Surg. 2004;8(2):97-102.[Crossref] [PubMed]
- Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol. 2011;65(4):689-97.[Crossref] [PubMed]
- Lieu TJ, Pandya AG. Melasma quality of life measures. Dermatol Clin. 2012;30(2):269-80.[Crossref] [PubMed]
- Doğramacı AÇ. [Melasma and quality of life]. Turkiye Klinikleri J Cosm Dermatol-Special Topics. 2011;4(2):23-6.[Link]
- Acıöz E, Gökdemir G, Köşlü A. [Quality of life in dermatology]. Turkderm. 2003;37(1):16-23.[Link]
- Oztürkcan S, Ermertcan AT, Eser E, Sahin MT. Cross validation of the Turkish version of dermatology life quality index. Int J Dermatol. 2006;45(11):1300-7.[Crossref] [PubMed]
- Gür AR, Köse O. [Quality of life and measurement in dermatology]. Turkiye Klinikleri J Dermatol. 2000;10(4):270-4.[Link]
- Bilaç C, Öztürkcan S. [Quality of life in dermatology]. Sağlıkta Birikim. 2006;1:48-58.
- Tamega Ade A, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermatol Venereol. 2013;27(2):151-6.[Crossref] [PubMed]
- Freitag FM, Cestari TF, Leopoldo LR, Paludo P, Boza JC. Effect of melasma on quality of life in a sample of women living in southern Brazil. J Eur Acad Dermatol Venereol. 2008;22(6):655-62.[Crossref] [PubMed]
- Dogramaci AC, Havlucu DY, Inandi T, Balkrishnan R. Validation of a melasma quality of life questionnaire for the Turkish language: the MelasQoL-TR study. J Dermatolog Treat. 2009;20(2):95-9.[Crossref] [PubMed]
- Maranzatto CF, Miot HA, Miot LD, Meneguin S. Psychometrican analysis and dimensional structure of the Brazilian version of melasma quality of life scale (MELASQoL-BP). An Bras Dermatol. 2016;91(4):422-8.[Crossref] [PubMed] [PMC]
- Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, Grimes P, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol. 2009;23(11):1254-62.[Crossref] [PubMed]
- Hexsel D, Lacerda DA, Cavalcante AS, Machado Filho CA, Kalil CL, Ayres EL, et al. Epidemiology of melasma in Brazilian patients: a multicenter study. Int J Dermatol. 2014;53(4):440-4.[Crossref] [PubMed]
- Guinot C, Cheffai S, Latreille J, Dhaoui MA, Youssef S, Jaber K, et al. Aggravating factors for melasma: a prospective study in 197 Tunisian patients. J Eur Acad Dermatol Venereol. 2010;24(9):1060-9.[Crossref] [PubMed]
- Harumi O, Goh CL. The effect of melasma on the quality of life in a sample of women living in Singapore. J Clin Aesthet Dermatol. 2016;9(1):21-4.[PubMed] [PMC]
- Sarkar R, Puri P, Jain RK, Singh A, Desai A. Melasma in men: a clinical, aetiological and histological study. J Eur Acad Dermatol Venereol. 2010;24(7):768-72.[Crossref] [PubMed]
- Türsen Ü. [Etiopathogenesis and clinical features in melasma]. Turkiye Klinikleri J Cosm Dermatol-Special Topics. 2011;4(2):16-22.[Link]
- Nicolaidou E, Antoniou C, Katsambas AD. Origin, clinical presentation, and diagnosis of facial hypermelanoses. Dermatol Clin. 2007;25(3):321-6.[Crossref] [PubMed]
- Sánchez NP, Sánchez JL, Vázquez-Botet M. Mechanisms of hyperpigmentation. P R Health Sci J. 1986;5(3):123-32.[PubMed]
- Balkrishnan R, Kelly AP, McMichael A, Torok H. Improved quality of life with effective treatment of facial melasma: the pigment trial. J Drugs Dermatol. 2004;3(4):377-81.[PubMed]
- Leeyaphan C, Wanitphakdeedecha R, Manuskiatti W, Kulthanan K. Measuring melasma patients' quality of life using willingness to pay and time trade-off methods in Thai population. BMC Dermatol. 2011;11:16.[Crossref] [PubMed] [PMC]
- Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol. 1999;141(6):1067-75.[Crossref] [PubMed]
- Schmitt J, Meurer M, Klon M, Frick KD. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol. 2008;158(2):351-9.[Crossref] [PubMed]
- Kulthanan K, Jiamton S, Wanitphakdeedecha R. The validity and reliability of the dermatology life quality index (DLQI) in thais. Thai J Dermatol. 2004;20:113-23.
- Ali R, Aman S, Nadeem M, Kazmi AH. Quality of life in patients of melasma. Journal of Pakistan Association of Dermatologists. 2013;23(2):143-8.[Link]
.: Process List